Unity Biotechnology (NASDAQ:UBX – Get Free Report) was upgraded by equities research analysts at Wedbush from a “neutral” rating to an “outperform” rating in a research note issued on Thursday, MarketBeat.com reports. The brokerage currently has a $4.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 120.99% from the company’s current price.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Unity Biotechnology in a research report on Tuesday.
Unity Biotechnology Price Performance
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Unity Biotechnology by 246.2% in the third quarter. Vanguard Group Inc. now owns 4,437,259 shares of the company’s stock valued at $1,753,000 after purchasing an additional 3,155,586 shares during the period. Renaissance Technologies LLC grew its holdings in Unity Biotechnology by 65.2% during the third quarter. Renaissance Technologies LLC now owns 1,582,369 shares of the company’s stock worth $625,000 after acquiring an additional 624,651 shares during the period. Acadian Asset Management LLC grew its holdings in Unity Biotechnology by 39.8% during the first quarter. Acadian Asset Management LLC now owns 389,893 shares of the company’s stock worth $435,000 after acquiring an additional 111,097 shares during the period. State Street Corp grew its holdings in Unity Biotechnology by 32.4% during the third quarter. State Street Corp now owns 172,640 shares of the company’s stock worth $68,000 after acquiring an additional 42,200 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Unity Biotechnology by 35.0% during the first quarter. Geode Capital Management LLC now owns 122,983 shares of the company’s stock worth $200,000 after acquiring an additional 31,882 shares during the period. Institutional investors and hedge funds own 18.45% of the company’s stock.
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
- Five stocks we like better than Unity Biotechnology
- What is an Earnings Surprise?
- Williams-Sonoma is a steal for buy-and-hold investors
- Dividend Payout Ratio Calculator
- A closer look at Warren Buffett’s latest surprise purchase
- What is a Mid Cap Stock? How to Invest
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.